The survival analysis results revealed that the overall survival(OS)and progression-free survival(PFS)of patients with AML with I1762V were significantly greater than those of wild-type patients(HR=0.57, P=0.030; HR=0.55, P=0.020), whereas the OS and PFS in patients with AML with DNMT3A mutation(with or without I1762V mutation)were lower than those of wild-type patients(HR=1.79, P=0.030; HR=1.74, P=0.040). This evidence concerns the gene DNMT3A and acute myeloid leukemia.